Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Higher Remission Rates in TNF Blocker-Naïve Patients Observed in Long-Term Vedolizumab Treatment
March 23, 2016
- Santen to Form JV with China’s Kerui for Generic Eye Drugs
March 23, 2016
- Opdivo Filed for Hodgkin’s Lymphoma in Japan
March 22, 2016
- Mochida to Codevelop Ajinomoto’s Oral Constipation Drug
March 22, 2016
- Jitsubo Aims to Launch Peptide Generic Drugs Using Its Unique Technologies
March 22, 2016
- Drug Makers Terminate Lysozyme, Pronase Sale after MHLW Panel Finds Them Ineffective
March 18, 2016
- Hisamitsu, Asahi Kasei End Sales Partnership for Neoxy Tape
March 18, 2016
- Meiji Seika Pharma, RIKEN Collaborate on Skin Regeneration Research
March 17, 2016
- Takeda, Orexigen to Wind Up Sales Collaboration for Contrave
March 17, 2016
- Reversal Agent for Prazaxa Filed in Japan: Boehringer
March 17, 2016
- Denka Seiken to Develop Intradermal Flu Vaccine
March 16, 2016
- J-TEC to Venture into CRO Biz for Regenerative Medicine
March 16, 2016
- Takeda Spins Out Investigational Stress Urinary Incontinence Drug to Yamada-Led US Firm
March 16, 2016
- Ethical Drug Sales Up 7.0% in January: Crecon Report
March 15, 2016
- Lilly Seeks to Block Launch of Evista Generics Approved in February
March 15, 2016
- AbbVie Launches Japan PIII Trials for All Hep C Genotypes
March 15, 2016
- MSD Files 2 Antivirals for Hep C Treatment in Japan
March 14, 2016
- Ono Beefing Up Organization for Safe Use of Opdivo, Eyes Larger Cancer Sales Force
March 11, 2016
- Mitsubishi Tanabe to Solely Market Janssen’s Simponi in Japan
March 11, 2016
- Takecab Most Heavily Pitched Drug in January: Anterio
March 11, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…